An overview of reviews with network meta-analyses comparing disease-modifying therapies for relapsing multiple sclerosis

IF 0.6 Q4 CLINICAL NEUROLOGY

Future Neurology Pub Date : 2023-08-22 DOI:10.2217/fnl-2023-0009

Christopher Drudge, I. Samjoo, R. Brennan, L. Badgujar, V. Khurana, Santosh Tiwari, N. Adlard, J. Bánházi

{"title":"An overview of reviews with network meta-analyses comparing disease-modifying therapies for relapsing multiple sclerosis","authors":"Christopher Drudge, I. Samjoo, R. Brennan, L. Badgujar, V. Khurana, Santosh Tiwari, N. Adlard, J. Bánházi","doi":"10.2217/fnl-2023-0009","DOIUrl":null,"url":null,"abstract":"Aim: An overview of published systematic reviews (SRs) with integrated network meta-analyses (NMAs) comparing disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) was conducted to help inform healthcare decision-making. Methods: We searched Embase, MEDLINE® and Cochrane Database of Systematic Reviews from inception to May 2023. Full-text studies evaluating annualized relapse rate (ARR) and/or confirmed disability progression (CDP) were qualitatively compared. Methodological quality was assessed using SR and NMA questionnaires. Results: Twenty-one SRs with integrated NMAs were included. Studies varied in their conduct and reporting of the SR, the included primary evidence, treatments, and cross-trial heterogeneity assessment and their conduct and reporting of NMAs. The quality of the studies was variable. Monoclonal antibody therapies were determined to be the most efficacious DMTs for reducing ARR and delaying CDP. Conclusion: Future analyses should carefully consider and clearly report methods and results to permit accurate interpretation of NMA findings and better inform decision-making.","PeriodicalId":12606,"journal":{"name":"Future Neurology","volume":" ","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2023-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/fnl-2023-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: An overview of published systematic reviews (SRs) with integrated network meta-analyses (NMAs) comparing disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) was conducted to help inform healthcare decision-making. Methods: We searched Embase, MEDLINE® and Cochrane Database of Systematic Reviews from inception to May 2023. Full-text studies evaluating annualized relapse rate (ARR) and/or confirmed disability progression (CDP) were qualitatively compared. Methodological quality was assessed using SR and NMA questionnaires. Results: Twenty-one SRs with integrated NMAs were included. Studies varied in their conduct and reporting of the SR, the included primary evidence, treatments, and cross-trial heterogeneity assessment and their conduct and reporting of NMAs. The quality of the studies was variable. Monoclonal antibody therapies were determined to be the most efficacious DMTs for reducing ARR and delaying CDP. Conclusion: Future analyses should carefully consider and clearly report methods and results to permit accurate interpretation of NMA findings and better inform decision-making.

查看原文本刊更多论文

网络荟萃分析比较复发性多发性硬化症疾病改善疗法的综述

目的:对已发表的系统评价(SRs)和综合网络荟萃分析(nma)进行综述，比较复发性多发性硬化症(RMS)的疾病改善疗法(dmt)，以帮助告知医疗保健决策。方法:检索Embase、MEDLINE®和Cochrane系统评价数据库，检索时间为成立至2023年5月。评估年复发率(ARR)和/或确认残疾进展(CDP)的全文研究进行了定性比较。采用SR问卷和NMA问卷评估方法学质量。结果:纳入21例合并nma的SRs。研究在SR的实施和报告、纳入的主要证据、治疗方法、跨试验异质性评估以及nma的实施和报告方面各不相同。研究的质量参差不齐。单克隆抗体治疗被认为是降低ARR和延缓CDP最有效的dmt。结论:未来的分析应仔细考虑并清楚地报告方法和结果，以便准确解释NMA发现并更好地为决策提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Neurology CLINICAL NEUROLOGY-

CiteScore

2.10

自引率

0.00%

发文量

期刊介绍： The neurological landscape is changing rapidly. From the technological perspective, advanced molecular approaches and imaging modalities have greatly increased our understanding of neurological disease, with enhanced prospects for effective treatments in common but very serious disorders such as stroke, epilepsy, multiple sclerosis and Parkinson’s disease. Nevertheless, at the same time, the healthcare community is increasingly challenged by the rise in neurodegenerative diseases consequent upon demographic changes in developed countries.